Pipeline

T-MSC programs by development stage

One pluripotent-derived platform. IMS001 is the lead clinical program. Additional T-MSC indications remain preclinical on published company materials.

Area Program

Autoimmune

Multiple sclerosis IMS001 · Phase 1/2a

Rare disease

Cerebral adrenoleukodystrophy T-MSC · Pre-clinical

Rare disease

Acute respiratory distress syndrome T-MSC · Pre-clinical

Bars follow the company’s published Overview chart. They are not a claim of completed trials or efficacy. Current stage should be confirmed with ImStem.

Explore IMS001 Explore the platform